Phaseline

Companies › TransThera Sciences (Nanjing)

TransThera Sciences (Nanjing): clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TT-00420 (tinengotinib)
Fibroblast growth factor receptor (FGFR) inhibitor
FGFR1, FGFR2, FGFR3, FGFR4Phase 3Cholangiocarcinoma; Cholangiocarcinoma Metastatic; Breast Cancer; Prostate Cancer (CRPC)Dec 2026
TT-01488
non-covalent reversible BTK inhibitor
BTKPhase 1B-Cell MalignanciesOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06057571TT-00420 (tinengotinib)Phase 2Cholangiocarcinoma MetastaticOncologyJul 2025
NCT05948475TT-00420 (tinengotinib)Phase 3CholangiocarcinomaOncologyDec 2026
NCT07498478TT-00420 (tinengotinib)Phase 2Breast CancerOncologyJun 2027
NCT05683717TT-01488Phase 1B-Cell MalignanciesOncologyOct 2028
NCT07871110TT-00420 (tinengotinib)Phase 2Prostate Cancer (CRPC)OncologyDec 2028

Targets

FGFR1 (1) FGFR2 (1) FGFR3 (1) FGFR4 (1) BTK (1)

Companies with the same targets

Tyra Biosciences Johnson & Johnson (Janssen) AstraZeneca Taiho Oncology Exelixis QED Therapeutics, a BridgeBio company Hutchmed Eisai BeOne Medicines Eli Lilly

Companies built like this

Elevar Therapeutics NOBO Medicine Nurix Therapeutics Clarity Pharmaceuticals TYK Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.